Semaglutide vs Adipotide.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, an acylated, structurally modified analog of the native incretin hormone GLP-1, engineered for once-weekly (injectable) or daily (oral) dosing through albumin binding and resistance to DPP-4 degradation. It is a fully approved prescription medicine marketed as Ozempic and Rybelsus (type 2 diabetes) and Wegovy (chronic weight management and, more recently, cardiovascular risk reduction). It is one of the most extensively studied peptide therapeutics in modern medicine, with large dedicated cardiovascular- and liver-outcome trials.

Adipotide (FTPP, also called prohibitin-targeting peptide-1) is an experimental chimeric peptidomimetic designed to destroy the blood supply of white fat rather than act as a hormone. It was developed by Kolonin, Arap and Pasqualini and colleagues as a proof-of-concept anti-obesity agent that targets the vasculature feeding adipose tissue. Adipotide has only ever been tested in animals; it has never completed human clinical trials and is not a medicine. It is discussed here strictly as a preclinical research compound.

Semaglutide binds and activates the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, the central nervous system, and elsewhere. In the pancreas it augments glucose-dependent insulin secretion and suppresses glucagon, lowering blood glucose with low intrinsic hypoglycemia risk because the effect is glucose-dependent. Centrally, it acts on hypothalamic and hindbrain appetite circuits to increase satiety and reduce food intake, and it slows gastric emptying; the combination drives weight loss. The molecule's C18 fatty-diacid side chain promotes albumin binding, which extends its half-life to roughly a week and underlies once-weekly dosing.

Adipotide links two functional parts: a homing peptide (sequence CKGGRAKDC) that binds prohibitin, a protein found in unusual abundance on the endothelial cells of white-fat blood vessels, and a pro-apoptotic sequence (a KLAKLAK-type domain) that triggers programmed cell death once internalized. By selectively killing the endothelial cells that supply fat depots, the peptide is intended to starve and shrink adipose tissue. This vascular-targeting approach is fundamentally different from appetite- or metabolism-based drugs like GLP-1 agonists. The concept was first demonstrated in rodents before testing in primates.

Human evidence is exceptionally strong and trial-backed rather than preclinical. The STEP 1 randomized trial (NEJM 2021, PMID 33567185) showed substantial, clinically meaningful weight loss versus placebo in adults with overweight/obesity without diabetes. SUSTAIN-6 (NEJM 2016, PMID 27633186) demonstrated reduced major adverse cardiovascular events in type 2 diabetes, and SELECT (NEJM 2023, PMID 37952131) showed a significant reduction in cardiovascular death, myocardial infarction, or stroke in people with obesity and established cardiovascular disease but without diabetes. The phase 3 ESSENCE trial (NEJM 2025, PMID 40305708) reported improvement in metabolic dysfunction-associated steatohepatitis (MASH). A documented limitation: the STEP 1 extension (Diabetes Obes Metab 2022, PMID 35441470) showed substantial weight regain after discontinuation, indicating benefits depend on continued use.

The original concept was shown in a mouse study by Kolonin and colleagues in Nature Medicine (2004), in which targeted ablation of adipose vasculature reduced fat mass. The most cited primate work, by Barnhart and colleagues in Science Translational Medicine (2011), treated spontaneously obese rhesus monkeys with adipotide for 28 days and reported roughly 7-15% body-weight loss along with reduced body fat on imaging and improved insulin resistance, while untreated controls were unchanged. These findings were promising but limited to small animal cohorts. Both studies share the constraints of early preclinical work: small numbers of animals, short exposure, no blinding comparable to a clinical trial, imaging and biochemical surrogates rather than clinical endpoints, and no follow-up long enough to show whether fat loss persists once treatment stops or whether ablated adipose vasculature regenerates. No completed, peer-reviewed human efficacy trials exist, and marketed or clinical human data are absent. All human-facing claims about adipotide therefore rest on animal data only. The gap is total rather than partial: there is no published human pharmacokinetic profile, no established human tolerated exposure, no efficacy signal in people, and no regulatory review of any human dataset. That places adipotide in a different category from approved obesity pharmacotherapy. Drugs such as semaglutide and tirzepatide reached approval through multi-thousand-participant randomised Phase 3 programs with blinded comparators, adjudicated safety events and, in semaglutide's case, dedicated cardiovascular outcome data, and their weight-loss estimates come from human trials rather than extrapolation from monkeys. Any comparison of adipotide's reported primate weight change with those human results is not a like-for-like comparison, and the current literature on adipotide is largely mechanistic and vascular-targeting research rather than obesity therapeutics. Nothing published to date establishes that the approach translates from rodents and monkeys to people at all.

The most common documented adverse effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, typically most pronounced early in treatment. Labeled warnings include a boxed warning for thyroid C-cell tumors based on rodent data (clinical relevance in humans remains uncertain), plus risks of pancreatitis, gallbladder disease, acute kidney injury from dehydration, and diabetic retinopathy complications in susceptible patients. Reduced lean mass alongside fat loss, and weight regain after stopping, are recognized. Use of unregulated, compounded, or research-grade "semaglutide" sold outside the approved supply chain carries additional, poorly characterized risks of contamination, mislabeling, and dosing errors.

The pivotal primate study identified dose-dependent renal toxicity, specifically renal tubular changes, as the main safety signal at doses that produced meaningful weight loss; these kidney effects were a major reason human development did not advance. That finding matters because it appeared at exposures tied to the desired effect rather than only at extreme excess, which is the pattern that most often halts a candidate before first-in-human work. Because adipotide has not been through human trials, its safety in people is unknown and unvalidated. No human dose has been shown to be tolerated, there is no characterised human adverse-event profile, no drug-interaction data, and no evidence about what monitoring would even detect harm early. A legitimate first-in-human program for a pro-apoptotic vascular-targeting agent of this kind would require intensive renal function monitoring, careful dose escalation with stopping rules, and independent safety oversight, none of which applies to informal use. Material sold online as research chemical is unregulated and not quality-controlled, meaning the identity, potency, purity, endotoxin content and sterility of the vial are unverified, and there is no manufacturer accountable for a bad batch or any channel for reporting injury. Adipotide is not approved for human use in any jurisdiction, and the combination of a known organ-toxicity signal in primates with an unregulated supply chain is the central safety consideration for this compound.

Semaglutide is FDA-approved (not investigational): Ozempic and Rybelsus for type 2 diabetes with cardiovascular risk-reduction indications, and Wegovy for chronic weight management and for cardiovascular risk reduction in adults with cardiovascular disease and overweight/obesity. Oral semaglutide for chronic weight management and a MASH indication are the most recent regulatory developments.

Adipotide is a preclinical/research compound with no FDA, EMA, or other regulatory approval for any use. It is not an approved drug or supplement, and no legitimate human therapeutic product exists. Any human use would be unapproved and unstudied.